GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2011

XenoPort and GSK’s Treatment for Restless Legs Syndrome Cleared in the U.S.

  • FDA approved XenoPort and U.S. partner GlaxoSmithKline’s (GSK) Horizant™ (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults.  Regulatory clearance in the U.S. was based on data from two 12-week studies. XenoPort claims the drug is the first in its class to be approved for the treatment of moderate-to-severe restless legs syndrome.

    XenoPort and GSK are separately carrying out Phase II development of gabapentin enacarbil in the U.S. for the treatment of post-herpetic neuralgia. The drug is being developed in Japan and other Asian countries for the restless legs syndrome indication by Astellas. Regulatory review in Japan is in progress.

    Under an amendment to the Horizant deal with GlaxoSmithKline, XenoPort now has the right to pursue development of the drug for certain other indications in the U.S. GSK remains responsible for commercialization of Horizant in the U.S. for all indications. In addition, XenoPort has reacquired all non-U.S. rights to the gabapentin enacarbil that were previously granted to GSK, excluding the Astellas territory.   

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »